Treace Medical Concepts
TMCI
135 hedge funds and large institutions have $278M invested in Treace Medical Concepts in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 46 reducing their positions, and 23 closing their positions.
736% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $145K
21% more capital invested
Capital invested by funds: $230M → $278M (+$48M)
9% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 23
1% more funds holding
Funds holding: 134 → 135 (+1)
7% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 46
3.84% less ownership
Funds ownership: 63.72% → 59.88% (-3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.97M |
| 2 |
JP Morgan Chase
New York
|
+$4.78M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$3.66M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.28M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.58M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.15M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.14M |
| 4 |
BlackRock
New York
|
-$2.73M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.26M |
TMCI Hedge Fund Activity: Q4 2024 in Review
135 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Treace Medical Concepts (TMCI) for Q4 2024, worth a combined $278M — up 21% from $230M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TMCI positions and 23 closed out — a net gain of 2 holders — while 43 added to existing stakes and 46 trimmed.
The largest buyer was UBS Group, adding an estimated $5.97M. The largest seller was Morgan Stanley, cutting an estimated $7.58M.
- 135 institutional investors held Treace Medical Concepts (TMCI) as of Q4 2024, up from 134 in Q3 2024.
- Funds reported $278M of Treace Medical Concepts stock for Q4 2024, up 21% quarter-over-quarter.
- 25 funds opened new Treace Medical Concepts positions in Q4 2024 and 23 closed out, a net change of +2 holders.
- The largest Treace Medical Concepts buyer in Q4 2024 was UBS Group, an estimated $5.97M added.
- The largest Treace Medical Concepts seller in Q4 2024 was Morgan Stanley, an estimated $7.58M sold.
Based on aggregated 13F filings for Q4 2024.